188 related articles for article (PubMed ID: 32928621)
1. Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures.
Harvey PD; Horan WP; Atkins AS; Stevens H; Welch M; Yuan J; Patterson TL; Narasimhan M; Keefe RSE
Schizophr Res; 2020 Sep; 223():297-304. PubMed ID: 32928621
[TBL] [Abstract][Full Text] [Related]
2. Validation of a Computerized test of Functional Capacity.
Keefe RSE; Davis VG; Atkins AS; Vaughan A; Patterson T; Narasimhan M; Harvey PD
Schizophr Res; 2016 Aug; 175(1-3):90-96. PubMed ID: 27091656
[TBL] [Abstract][Full Text] [Related]
3. Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning.
Ventura J; Welikson T; Ered A; Subotnik KL; Keefe RSE; Hellemann GS; Nuechterlein KH
Early Interv Psychiatry; 2020 Feb; 14(1):106-114. PubMed ID: 31183960
[TBL] [Abstract][Full Text] [Related]
4. Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance.
Ruse SA; Harvey PD; Davis VG; Atkins AS; Fox KH; Keefe RS
Schizophr Res Cogn; 2014 Mar; 1(1):e21-e26. PubMed ID: 25083416
[TBL] [Abstract][Full Text] [Related]
5. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
[TBL] [Abstract][Full Text] [Related]
6. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.
Burton CZ; Vella L; Harvey PD; Patterson TL; Heaton RK; Twamley EW
Schizophr Res; 2013 May; 146(1-3):244-8. PubMed ID: 23507359
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
[TBL] [Abstract][Full Text] [Related]
8. Effects of an extrinsic motivator on the evaluation of cognitive and daily living functions in patients with schizophrenia.
Kim SJ; Jung DU; Moon JJ; Jeon DW; Seo YS; Jung SS; Lee YC; Kim JE
Schizophr Res; 2020 Jun; 220():172-178. PubMed ID: 32241751
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).
Atkins AS; Khan A; Ulshen D; Vaughan A; Balentin D; Dickerson H; Liharska LE; Plassman B; Welsh-Bohmer K; Keefe RSE
J Prev Alzheimers Dis; 2018; 5(4):216-234. PubMed ID: 30298179
[TBL] [Abstract][Full Text] [Related]
10. Calibration and cross-validation of MCCB and CogState in schizophrenia.
Lees J; Applegate E; Emsley R; Lewis S; Michalopoulou P; Collier T; Lopez-Lopez C; Kapur S; Pandina GJ; Drake RJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3873-82. PubMed ID: 26018529
[TBL] [Abstract][Full Text] [Related]
11. Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia.
Lindenmayer JP; Goldring A; Borne S; Khan A; Keefe RSE; Insel BJ; Thanju A; Ljuri I; Foreman B
Schizophr Res; 2020 Sep; 223():166-172. PubMed ID: 32690346
[TBL] [Abstract][Full Text] [Related]
12. Utility of the UCSD Performance-based Skills Assessment-Brief Japanese version: discriminative ability and relation to neurocognition.
Sumiyoshi C; Takaki M; Okahisa Y; Patterson TL; Harvey PD; Sumiyoshi T
Schizophr Res Cogn; 2014 Sep; 1(3):137-143. PubMed ID: 29379746
[TBL] [Abstract][Full Text] [Related]
13. An empirical evaluation of the MATRICS Consensus Cognitive Battery in bipolar disorder.
Van Rheenen TE; Rossell SL
Bipolar Disord; 2014 May; 16(3):318-25. PubMed ID: 24119238
[TBL] [Abstract][Full Text] [Related]
14. A case control study of association between cognition and functional capacity in schizophrenia.
Narayanan SS; Bhatia T; Velligan DI; Nimgaonkar VL; Deshpande SN
Schizophr Res; 2015 Dec; 169(1-3):165-168. PubMed ID: 26527248
[TBL] [Abstract][Full Text] [Related]
15. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC; Buchanan RW; Keefe RS; Kern R; McMahon RP; Green MF; Lieberman J; Goff DC; Csernansky JG; McEvoy JP; Jarskog F; Seidman LJ; Gold JM; Kimhy D; Nolan KS; Barch DS; Ball MP; Robinson J; Marder SR
Schizophr Res; 2012 Apr; 136(1-3):25-31. PubMed ID: 22169248
[TBL] [Abstract][Full Text] [Related]
16. Relationship between disability self-awareness and cognitive and daily living function in schizophrenia.
Kim SJ; Jung DU; Moon JJ; Jeon DW; Seo YS; Jung SS; Lee YC; Kim JE; Kim YS
Schizophr Res Cogn; 2021 Mar; 23():100192. PubMed ID: 33294392
[TBL] [Abstract][Full Text] [Related]
17. Cognition-UPSA score relationships: a further analysis of Silverstein et al. (2010) data and some caveats.
Silverstein SM; All SD; Jaeger J
Psychiatry Res; 2011 May; 187(3):424-31. PubMed ID: 21216013
[TBL] [Abstract][Full Text] [Related]
18. Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery.
Bezdicek O; Michalec J; Kališová L; Kufa T; Děchtěrenko F; Chlebovcová M; Havlík F; Green MF; Nuechterlein KH
Schizophr Res; 2020 Apr; 218():85-92. PubMed ID: 32089475
[TBL] [Abstract][Full Text] [Related]
19. Neurocognition, functional capacity, and functional outcomes: the cost of inexperience.
Holshausen K; Bowie CR; Mausbach BT; Patterson TL; Harvey PD
Schizophr Res; 2014 Feb; 152(2-3):430-4. PubMed ID: 23978775
[TBL] [Abstract][Full Text] [Related]
20. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment.
McCleery A; Ventura J; Kern RS; Subotnik KL; Gretchen-Doorly D; Green MF; Hellemann GS; Nuechterlein KH
Schizophr Res; 2014 Aug; 157(1-3):33-9. PubMed ID: 24888526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
